Equillium, Inc. (EQ)
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Equillium, Inc.
- EQ504READOUTCash runway at this date: 2yr
Trials need funding. See this company's dilution risk and cash position.
- $20M upfront/ $50M totalOct 26, 2026EQ504
- Phase 3Terminated
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Itolizumab, EQ001 Placebo
Graft Versus Host Disease, GVHD +3
NCT05263999Enrollment158StartApr 2022Primary CompletionApr 2025CompletionMay 2025 - Phase 2Withdrawn
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
BNZ-1, Normal saline
Alopecia Areata, Alopecia Totalis +1
NCT03532958Enrollment0StartOct 2021est.Primary CompletionNov 2022est.CompletionNov 2022est. - Phase 2Completed
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
EQ101
Alopecia Areata, Alopecia +2
NCT05589610Enrollment36StartDec 2022Primary CompletionMar 2024CompletionApr 2024 - Phase 1Not yet recruiting
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
EQ504, EQ504 Placebo
Ulcerative Colitis
NCT07869225Enrollment70StartOct 2026est.Primary CompletionApr 2027est.READOUTCompletionMay 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Terminated | Itolizumab, EQ001 Placebo | NCT05263999 |
| Phase 2 | Withdrawn | BNZ-1, Normal saline | NCT03532958 |
| Phase 2 | Completed | EQ101 | NCT05589610 |
| Phase 1 | Not yet recruiting | EQ504, EQ504 Placebo | NCT07869225 |